Literature DB >> 33977470

Precise Characterization of KRAS4B Proteoforms by Combining Immunoprecipitation with Top-Down Mass Spectrometry.

Lauren M Adams1, Caroline J DeHart2, Neil L Kelleher3,4,5.   

Abstract

The characterization of biologically relevant post-translational modifications (PTMs) on KRAS4B has historically been carried out through methodologies such as immunoblotting with PTM-specific antibodies or peptide-based proteomic methods. While these methods have the potential to identify a given PTM on KRAS4B, they are incapable of characterizing or distinguishing the different molecular forms or proteoforms of KRAS4B from those of related RAS isoforms. We present a method that combines immunoprecipitation of KRAS4B with top-down mass spectrometry (IP-TDMS), thus enabling the precise characterization of intact KRAS4B proteoforms. We provide detailed protocols for the IP, LC-MS/MS, and data analysis comprising a successful IP-TDMS assay in the contexts of cancer cell lines and tissue samples.

Entities:  

Keywords:  Immunoprecipitation; Intact protein; Isoform; Proteoform; RAS; Top-down mass spectrometry

Mesh:

Substances:

Year:  2021        PMID: 33977470      PMCID: PMC8543976          DOI: 10.1007/978-1-0716-1190-6_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

1.  Informatics and multiplexing of intact protein identification in bacteria and the archaea.

Authors:  F Meng; B J Cargile; L M Miller; A J Forbes; J R Johnson; N L Kelleher
Journal:  Nat Biotechnol       Date:  2001-10       Impact factor: 54.908

2.  A comprehensive pipeline for translational top-down proteomics from a single blood draw.

Authors:  Timothy K Toby; Luca Fornelli; Kristina Srzentić; Caroline J DeHart; Josh Levitsky; John Friedewald; Neil L Kelleher
Journal:  Nat Protoc       Date:  2019-01       Impact factor: 13.491

Review 3.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

Authors:  Adrienne D Cox; Channing J Der; Mark R Philips
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

4.  Bioinformatics Analysis of Top-Down Mass Spectrometry Data with ProSight Lite.

Authors:  Caroline J DeHart; Ryan T Fellers; Luca Fornelli; Neil L Kelleher; Paul M Thomas
Journal:  Methods Mol Biol       Date:  2017

5.  Advancing Top-down Analysis of the Human Proteome Using a Benchtop Quadrupole-Orbitrap Mass Spectrometer.

Authors:  Luca Fornelli; Kenneth R Durbin; Ryan T Fellers; Bryan P Early; Joseph B Greer; Richard D LeDuc; Philip D Compton; Neil L Kelleher
Journal:  J Proteome Res       Date:  2016-12-02       Impact factor: 4.466

Review 6.  ras genes.

Authors:  M Barbacid
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

7.  Proteoforms as the next proteomics currency.

Authors:  Lloyd M Smith; Neil L Kelleher
Journal:  Science       Date:  2018-03-08       Impact factor: 47.728

Review 8.  A New View of Ras Isoforms in Cancers.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Mayukh Chakrabarti; Hyunbum Jang
Journal:  Cancer Res       Date:  2015-12-10       Impact factor: 12.701

Review 9.  Thematic review series: lipid posttranslational modifications. CAAX modification and membrane targeting of Ras.

Authors:  Latasha P Wright; Mark R Philips
Journal:  J Lipid Res       Date:  2006-03-16       Impact factor: 5.922

10.  Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk.

Authors:  Ioanna Ntai; Luca Fornelli; Caroline J DeHart; Josiah E Hutton; Peter F Doubleday; Richard D LeDuc; Alexandra J van Nispen; Ryan T Fellers; Gordon Whiteley; Emily S Boja; Henry Rodriguez; Neil L Kelleher
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-02       Impact factor: 11.205

View more
  1 in total

Review 1.  Deciphering combinatorial post-translational modifications by top-down mass spectrometry.

Authors:  Jennifer S Brodbelt
Journal:  Curr Opin Chem Biol       Date:  2022-06-29       Impact factor: 8.972

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.